March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Intravitreal Injection Of Bevacizumab For Naive Myopic Choroidal Neovascularization: Results Obtained After 18 Months Of Treatment
Author Affiliations & Notes
  • flore DE BATS
    Croix Rousse Hospital, Lyon, LYON, France
  • Jean Daniel Grange
    Croix Rousse Hospital, Lyon, LYON, France
  • Philippe Denis
    Croix Rousse Hospital, Lyon, LYON, France
  • Laurent Kodjikian
    Croix Rousse Hospital, Lyon, LYON, France
  • Footnotes
    Commercial Relationships  flore De bats, None; Jean Daniel Grange, None; Philippe Denis, None; Laurent Kodjikian, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2948. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      flore DE BATS, Jean Daniel Grange, Philippe Denis, Laurent Kodjikian; Intravitreal Injection Of Bevacizumab For Naive Myopic Choroidal Neovascularization: Results Obtained After 18 Months Of Treatment. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2948. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Choroidal neovascularization is a complication of high myopia which can reduce the visual prognosis in young patients. The purpose of this study was to evaluate the efficacity and safety of bevacizumab in the first-line treatment of myopic choroidal neovascularization.

Methods: : We report a retrospective study of patients with subfoveal or juxtafoveal choroidal neovascularization associated with pathologic myopia treated with intravitreal injection of bevacizumab in Lyon, France, from January 2009 to June 2010. Best-corrected visual acuity, ocular pressure, fundus examination, optical coherence tomography and fluorescein angiography were performed for each patient at baseline and monthly. Indications for retreatment were persistent on recurrence of exsudative activity.

Results: : The study included 7 eyes of 7 patients with a mean of age of 44 and spherical equivalent refractive error of -12 diopters. The mean follow-up time was 18 months. The mean number of intravitreal injections was 3 at the end of the first year. 6 patients maintained or improved their vision. No injection complications or drug-related side effects were noted during the follow-up period.

Conclusions: : In this study, intravitreal injection of bevacizumab seems to be a safe and effective treatment for myopic choroidal neovascularization resulting in functionnal and anatomic improvement.

Keywords: macula/fovea • myopia • neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×